Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity

Patent metadata

Field	Value
Publication number	US-11225673-B2
Application number	US-201816124274-A
Country	US
Kind code	B2
Filing date	Sep 7, 2018
Priority date	Nov 21, 2008
Publication date	Jan 18, 2022
Grant date	Jan 18, 2022

Abstract

The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.

First claim

The invention claimed is:

1. A recombinant modified vaccinia Ankara (MVA) virus vector that stably encodes homologous sequences, the vector comprising:
first and second nucleotide sequences of at least 1500 nucleotides each, each coding for at least 500 amino acids, wherein at least 150 continuous amino acids encoded by each of the two nucleotide sequences have at least 75% amino acid identity;
wherein at least one of the first and second nucleotides has at least 400 substituted nucleotides and wherein the substituted nucleotides do not alter the identical amino acids encoded by said two nucleotide sequences; and
wherein the first and second nucleotide sequences differ by at least 400 nucleotides; and
wherein the first and second nucleotides share stretches of identity of no more than 9 contiguous nucleotides; and wherein the first and second nucleotide sequences each encode a RSV protein.

2. The recombinant MVA virus vector of claim 1 , wherein first and second nucleotide sequences encode a full-length RSV-F protein and a truncated RSV-F protein.

3. The recombinant MVA virus vector of claim 1 , wherein the first and second nucleotide sequences encode the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:4, respectively.

4. The recombinant MVA virus vector of claim 3 , wherein the first and second nucleotide sequences comprise the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO:2, respectively.

Assignees

• Bavarian Nordic As

Inventors

• Steigerwald Robin

Classifications

• C12N15/86 Primary

  Viral vectors · CPC title

• C12N2740/11022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2760/14122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2710/24151

  Methods of production or purification of viral material · CPC title

• C12N15/64 Primary

  General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host · CPC title